CJC-1295 / Ipamorelin Stack vs Melanotan II
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 / Ipamorelin Stack
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.
Full profileMelanotan II
Melanotan II (MT-II) is a cyclic lactam analog of alpha-melanocyte stimulating hormone (α-MSH) that acts as a potent, non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R). Developed at the University of Arizona in the late 1980s, it produces eumelanin-driven skin darkening (tanning) via MC1R, sexual arousal and spontaneous erections via MC4R, and appetite suppression via MC3R/MC4R. Bremelanotide (PT-141) — now FDA-approved for female sexual dysfunction — was derived from Melanotan II.
Full profile| CJC-1295 / Ipamorelin Stack | Melanotan II | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination | MT-II, MTII, Cyclo[Nle4,D-Phe7]-α-MSH |
| Evidence | FDA-approved | Research-stage |
| Dosing range | 100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols) | 250mcg–1000mcg mcg, Daily during loading phase; 2–3x weekly for maintenance |
| Administration | Subcutaneous injection (both compounds), Administered together in the same injection | Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability) |
| Key side effects | Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose) | Nausea (most common — especially first 30–60 minutes post-injection), Facial flushing, Spontaneous erections (males — often unwanted at higher doses), Fatigue / yawning post-injection |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while Melanotan II is research-stage.
- Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; Melanotan II — Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability).
- Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); Melanotan II is Daily during loading phase; 2–3x weekly for maintenance.
- Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 3 for Melanotan II.
How each works
CJC-1295 / Ipamorelin Stack
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.
Melanotan II
Melanotan II's broad melanocortin receptor agonism produces a constellation of effects across multiple systems. MC1R activation in melanocytes upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis, producing UV-independent skin darkening. MC4R activation in the CNS and spinal cord drives sexual arousal and erectogenic effects more potent than most PDE5 inhibitors, and also produces appetite suppression and reduced food intake (the same pathway exploited by weight-loss drugs targeting the melanocortin system). MC3R activation contributes to energy homeostasis effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.